By leveraging real‐world data, this investigation sought to provide clinically relevant insights into the differential efficacy and safety of PD‐1 and PD‐L1 inhibitors and refine therapeutic strategies for the management of NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.